Oramed Pharmaceutical, Inc. Adds to its Scientific Advisory Board
10 January 2007 - 1:05AM
PR Newswire (US)
JERUSALEM, Jan. 9 /PRNewswire-FirstCall/ -- Oramed Pharmaceutical
Inc. (OTC Bulletin Board: ORMP; Frankfurt: OJU) has added Prof.
Itamar Raz to its established scientific advisory board. Itamar
Raz, M.D. is a professor of Internal Medicine at Hadassah
University Medical Center and the head of the Diabetes Unit at
Hadassah. During 1992-2005 he served as the President of the Israel
Diabetes Association. He is the head of the Israel National Council
of Diabetes and president of D-Cure, a foundation that supports
research in the field of diabetes. Professor Raz maintains an
active clinical research program. He is the director of the newly
formed Hadassah Diabetes Research Center, which focuses on
experimental and innovative therapies for diabetes and president of
the Israel Diabetes Research Group. He is a member of several
editorial boards, including the Israeli Medical Association Journal
(IMAJ) and RDS. "We are pleased that Professor Raz has agreed to
join Oramed Pharmaceuticals' Scientific Advisory Board," stated
Nadav Kidron, CEO of Oramed Pharmaceuticals. "He brings a wealth of
knowledge and experience in the field of diabetes therapies to the
Company. We believe that Professor Raz's presence on our Board will
help us to advance our research and development of the oral insulin
soft gel capsule as well as other products" Professor Raz has
extensively published in the area of diabetes mellitus with over
170 publications to his credit. His significant contributions to
diabetes research will help strengthen the existing Advisory Board
as Oramed moves forward with human clinical trials for their
insulin soft gel capsule and other developing technologies. About
Oramed Pharmaceuticals, Inc: Oramed Pharmaceuticals' is an Israeli
based company focused on the development of oral delivery solutions
based on proprietary technology. Diabetes is one of the most
rapidly growing diseases in the world and is one that requires
constant and often unpleasant monitoring and drug therapy regimen.
Oramed is currently developing an orally soft gel insulin capsule
for the treatment of diabetes. The Company is also pursuing the
development of oral delivery solutions for other drugs and
vaccines. For more information on Oramed Pharmaceuticals please
visit our website: http://www.oramedpharma.com/ Legal Notice
Regarding Forward Looking Statements This news release contains
statements, which may constitute "forward- looking statements".
Those statements include statements regarding the intent, belief or
current expectations of Oramed Pharmaceutical Inc., and members of
our management as well as the assumptions on which such statements
are based. Forward-looking statements in this release include: that
we are currently developing an orally ingestible soft gel insulin
capsule for the treatment of diabetes and for other diseases.
Factors which may significantly change or prevent our forward
looking statements from fruition include that oral insulin gel
capsules may not be suitable for our intended purposes; we may be
unsuccessful in developing any products; we may be unable to raise
funds and resources to pursue research and development; we may be
unable to successfully defend our patents from infringement by
third parties, there is a risk that our patents may be subsequently
shown to be invalid or infringe the patents of others, our products
may never gain FDA or other regulatory body approval for human
consumption and we may be unable to successfully commercialize our
future products. Readers should refer to our most recent 10-KSB
filed on Edgar. DATASOURCE: Oramed Pharmaceutical, Inc. CONTACT:
Investor Relations: Vinisha Agnihotri for Oramed Pharmaceuticals,
Inc., +1-646-467-2252, Web site: http://www.oramedpharma.com/
Copyright